{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:24:44Z","timestamp":1768461884665,"version":"3.49.0"},"reference-count":155,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation, USA","doi-asserted-by":"publisher","award":["LOPES21I0"],"award-info":[{"award-number":["LOPES21I0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation, USA","doi-asserted-by":"publisher","award":["LOPES23GO"],"award-info":[{"award-number":["LOPES23GO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation, USA","doi-asserted-by":"publisher","award":["DL57\/2016"],"award-info":[{"award-number":["DL57\/2016"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation, USA","doi-asserted-by":"publisher","award":["UIDB\/04046\/2020"],"award-info":[{"award-number":["UIDB\/04046\/2020"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation, USA","doi-asserted-by":"publisher","award":["UIDP\/04047\/2020"],"award-info":[{"award-number":["UIDP\/04047\/2020"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FCT, Portugal","award":["LOPES21I0"],"award-info":[{"award-number":["LOPES21I0"]}]},{"name":"FCT, Portugal","award":["LOPES23GO"],"award-info":[{"award-number":["LOPES23GO"]}]},{"name":"FCT, Portugal","award":["DL57\/2016"],"award-info":[{"award-number":["DL57\/2016"]}]},{"name":"FCT, Portugal","award":["UIDB\/04046\/2020"],"award-info":[{"award-number":["UIDB\/04046\/2020"]}]},{"name":"FCT, Portugal","award":["UIDP\/04047\/2020"],"award-info":[{"award-number":["UIDP\/04047\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The implementation of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator drugs into clinical practice has been attaining remarkable therapeutic outcomes for CF, a life-threatening autosomal recessive genetic disease. However, there is elevated CFTR allelic heterogeneity, and various individuals carrying (ultra)rare CF genotypes remain without any approved modulator therapy. Novel translational model systems based on individuals\u2019 own cells\/tissue are now available and can be used to interrogate in vitro CFTR modulator responses and establish correlations of these assessments with clinical features, aiming to provide prediction of therapeutic effectiveness. Furthermore, because CF is a progressive disease, assessment of biomarkers in routine care is fundamental in monitoring treatment effectiveness and disease severity. In the first part of this review, we aimed to focus on the utility of individual-derived in vitro models (such as bronchial\/nasal epithelial cells and airway\/intestinal organoids) to identify potential responders and expand personalized CF care. Thereafter, we discussed the usage of CF inflammatory biomarkers derived from blood, bronchoalveolar lavage fluid, and sputum to routinely monitor treatment effectiveness and disease progression. Finally, we summarized the progress in investigating extracellular vesicles as a robust and reliable source of biomarkers and the identification of microRNAs related to CFTR regulation and CF inflammation as novel biomarkers, which may provide valuable information for disease prognosis.<\/jats:p>","DOI":"10.3390\/jpm14010093","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T11:15:01Z","timestamp":1705317301000},"page":"93","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis"],"prefix":"10.3390","volume":"14","author":[{"given":"Mafalda","family":"Bacalhau","sequence":"first","affiliation":[{"name":"Biosystems & Integrative Sciences Institute (BioISI), Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-8550","authenticated-orcid":false,"given":"Mariana","family":"Camargo","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Urology, Sao Paulo Federal University, Sao Paulo 04039-060, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-9359","authenticated-orcid":false,"given":"Miqu\u00e9ias","family":"Lopes-Pacheco","sequence":"additional","affiliation":[{"name":"Biosystems & Integrative Sciences Institute (BioISI), Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine","volume":"10","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.2772657","article-title":"Identification of the cystic fibrosis gene: Chromosome walking and jumping","volume":"245","author":"Rommens","year":"1989","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: Genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/JEP.S255377","article-title":"Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis","volume":"13","author":"Pinto","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1164\/rccm.201507-1281OC","article-title":"Morphometric Analysis of Explant Lungs in Cystic Fibrosis","volume":"193","author":"Boon","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation","volume":"181","author":"Farrell","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.jpeds.2016.09.068","article-title":"Diagnosis of Cystic Fibrosis in Nonscreened Populations","volume":"181S","author":"Sosnay","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_10","unstructured":"(2023, December 01). Cystic Fibrosis Mutation Database (CFTR1 Database). Available online: http:\/\/www.genet.sickkids.on.ca\/."},{"key":"ref_11","unstructured":"(2023, December 01). Clinical and Function Translation of CFTR (CFTR2 Database). Available online: https:\/\/cftr2.org\/."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1099-0496(200101)31:1<1::AID-PPUL1000>3.0.CO;2-T","article-title":"European Epidemiologic Registry of Cystic Fibrosis (ERCF): Comparison of major disease manifestations between patients with different classes of mutations","volume":"31","author":"Koch","year":"2001","journal-title":"Pediatr. Pulmonol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2213-2600(16)30188-6","article-title":"Classification of CFTR mutation classes","volume":"4","author":"Marson","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/14656566.2023.2230129","article-title":"The revolution of personalized pharmacotherapies for cystic fibrosis: What does the future hold?","volume":"24","author":"Oliver","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: Current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","article-title":"Discovery of CFTR modulators for the treatment of cystic fibrosis","volume":"16","author":"Pedemonte","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor\u2013Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Munck","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bacalhau, M., Camargo, M., Magalh\u00e3es-Ghiotto, G.A.V., Drumond, S., Castelletti, C.H.M., and Lopes-Pacheco, M. (2023). Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030410"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e95734","DOI":"10.1172\/jci.insight.95734","article-title":"Nasospheroids permit measurements of CFTR-dependent fluid transport","volume":"2","author":"Guimbellot","year":"2017","journal-title":"JCI Insight"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/520609a","article-title":"Personalized medicine: Time for one-person trials","volume":"520","author":"Schork","year":"2015","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jclinepi.2015.05.004","article-title":"CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement","volume":"76","author":"Vohra","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Silva, I.A.L., Laselva, O., and Lopes-Pacheco, M. (2022). Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis. J. Pers. Med., 12.","DOI":"10.3390\/jpm12081321"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/jpet.109.154146","article-title":"Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators","volume":"330","author":"Caputo","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/humu.23741","article-title":"Two CFTR mutations within codon 970 differently impact on the chloride channel functionality","volume":"40","author":"Amato","year":"2019","journal-title":"Hum. Mutat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/cts.12927","article-title":"G970R-CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect","volume":"14","author":"Fidler","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"C866","DOI":"10.1152\/ajpcell.00404.2009","article-title":"Influence of cell background on pharmacological rescue of mutant CFTR","volume":"298","author":"Pedemonte","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"C872","DOI":"10.1152\/ajpcell.00507.2010","article-title":"Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling","volume":"301","author":"Sondo","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2022.12.005","article-title":"Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation\u2019s stability and gating defects are dependent on cell background","volume":"22","author":"Tomati","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Sepahzad, A., Morris-Rosendahl, D.J., and Davies, J.C. (2021). Cystic fibrosis lung disease modifiers and their relevance in the new era of precision medicine. Genes, 12.","DOI":"10.3390\/genes12040562"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e99385","DOI":"10.1172\/jci.insight.99385","article-title":"Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies","volume":"3","author":"Brewington","year":"2018","journal-title":"JCI Insight"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1113\/JP282143","article-title":"Correlating genotype with phenotype using CFTR-mediated whole-cell Cl\u2212 currents in human nasal epithelial cells","volume":"600","author":"Noel","year":"2022","journal-title":"J. Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1513\/AnnalsATS.202001-082RL","article-title":"Correlation between ivacaftor-induced CFTR activation in airway epithelial cells and improved lung function: A proof-of-concept study","volume":"17","author":"Debley","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ppul.23659","article-title":"In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies","volume":"52","author":"McGarry","year":"2017","journal-title":"Pediatr. Pulmonol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3389\/fped.2020.00536","article-title":"Functional Profiling of CFTR-Directed Therapeutics Using Pediatric Patient-Derived Nasal Epithelial Cell Models","volume":"8","author":"Park","year":"2020","journal-title":"Front. Pediatr."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Terlizzi, V., Pesce, E., Capurro, V., Tomati, V., Lena, M., Pastorino, C., Bocciardi, R., Zara, F., Centrone, C., and Taccetti, G. (2023). Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076576"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Allan, K.M., Astore, M.A., Kardia, E., Wong, S.L., Fawcett, L.K., Bell, J.L., Visser, S., Chen, P.-C., Griffith, R., and Jaffe, A. (2023). Q1291H-CFTR molecular dynamics simulations and ex vivo theratyping in nasal epithelial models and clinical response to elexacaftor\/tezacaftor\/ivacaftor in a Q1291H\/F508del patient. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1148501"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcf.2017.06.010","article-title":"Detection of CFTR function and modulation in primary human nasal cell spheroids","volume":"17","author":"Brewington","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"L119","DOI":"10.1152\/ajplung.00639.2020","article-title":"CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling","volume":"321","author":"Anderson","year":"2021","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e100300","DOI":"10.15252\/embj.2018100300","article-title":"Long-term expanding human airway organoids for disease modeling","volume":"38","author":"Sachs","year":"2019","journal-title":"EMBO J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1702529","DOI":"10.1183\/13993003.02529-2017","article-title":"Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function","volume":"52","author":"Janssens","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jcf.2019.10.022","article-title":"Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations","volume":"19","author":"Berkers","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1902426","DOI":"10.1183\/13993003.02426-2019","article-title":"Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis","volume":"57","author":"Ramalho","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jcf.2022.01.008","article-title":"Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype","volume":"21","author":"Aalbers","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1164\/rccm.202004-1200LE","article-title":"Comparison of organoid swelling and in vivo biomarkers of cftr function to determine effects of lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for the f508del mutation","volume":"202","author":"Graeber","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2100508","DOI":"10.1183\/13993003.00508-2021","article-title":"Forskolin-induced Organoid Swelling is Associated with Long-term CF Disease Progression","volume":"60","author":"Muilwijk","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Lefferts, J.W., Bierlaagh, M.C., Kroes, S., Nieuwenhuijze, N.D.A., Sonneveld van Kooten, H.N., Niem\u00f6ller, P.J., Verburg, T.F., Janssens, H.M., Muilwijk, D., and van Beuningen, S.F.B. (2023). CFTR Function Restoration upon Elexacaftor\/Tezacaftor\/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914539"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2201341","DOI":"10.1183\/13993003.01341-2022","article-title":"Rectal organoid-guided CFTR modulator therapy restores lung function in a CF patient with the rare 1677delTA\/R334W genotype","volume":"60","author":"Mitropoulou","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Kondratyeva, E., Melyanovskaya, Y., Efremova, A., Krasnova, M., Mokrousova, D., Bulatenko, N., Petrova, N., Polyakov, A., Adyan, T., and Kovalskaia, V. (2023). Clinical and Genetic Characteristics of a Patient with Cystic Fibrosis with a Complex Allele [E217G;G509D] and Functional Evaluation of the CFTR Channel. Genes, 14.","DOI":"10.3390\/genes14091705"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Hadida","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Hadida","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-62703-125-7_8","article-title":"Human nasal and tracheo-bronchial respiratory epithelial cell culture","volume":"945","author":"Fulcher","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","article-title":"ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells","volume":"180","author":"Liu","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.stem.2016.05.012","article-title":"Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells","volume":"19","author":"Mou","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nprot.2016.174","article-title":"Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens","volume":"12","author":"Liu","year":"2017","journal-title":"Nat. Protoc."},{"key":"ref_67","first-page":"e50646","article-title":"Culturing of human nasal epithelial cells at the air liquid interface","volume":"80","author":"Brighton","year":"2013","journal-title":"J. Vis. Exp."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2100908","DOI":"10.1183\/13993003.00908-2021","article-title":"Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells","volume":"58","author":"Sette","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.apsb.2020.01.011","article-title":"Conditional reprogramming: Next generation cell culture","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-018-0393-7","article-title":"A revised airway epithelial hierarchy includes CFTR-expressing ionocytes","volume":"560","author":"Montoro","year":"2018","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-018-0394-6","article-title":"A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte","volume":"560","author":"Plasschaert","year":"2018","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1164\/rccm.202008-3198OC","article-title":"Secretory cells dominate airway CFTR expression and function in human airway superficial epithelia","volume":"203","author":"Okuda","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1165\/rcmb.2007-0325OC","article-title":"Nasal epithelial cells as surrogates for bronchial epithelial cells in airway inflammation studies","volume":"39","author":"McDougall","year":"2008","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jcf.2004.05.026","article-title":"Transepithelial electrical measurements with the Ussing chamber","volume":"3","author":"Li","year":"2004","journal-title":"J. Cyst. Fibros."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jcf.2004.05.046","article-title":"The patch-clamp and planar lipid bilayer techniques: Powerful and versatile tools to investigate the CFTR Cl\u2212 channel","volume":"3","author":"Sheppard","year":"2004","journal-title":"J. Cyst. Fibros."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Graeber, S.Y., Bal\u00e1zs, A., Ziegahn, N., Rubil, T., Vitzthum, C., Piehler, L., Drescher, M., Seidel, K., Rohrbach, A., and R\u00f6hmel, J. (2023). Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512365"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1164\/rccm.201808-1436LE","article-title":"Might brushed nasal cells be a surrogate for CFTR modulator clinical response?","volume":"199","author":"Pranke","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"15511","DOI":"10.1038\/s41598-021-94798-x","article-title":"Validation of nasospheroids to assay CFTR functionality and modulator responses in cystic fibrosis","volume":"11","author":"Calucho","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Liu, Z., Anderson, J.D., Deng, L., Mackay, S., Bailey, J., Kersh, L., Rowe, S.M., and Guimbellot, J.S. (2020). Human nasal epithelial organoids for therapeutic development in cystic fibrosis. Genes, 11.","DOI":"10.3390\/genes11060603"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","article-title":"Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett\u2019s epithelium","volume":"141","author":"Sato","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1152\/physrev.00026.2001","article-title":"Electrolyte transport in the mammalian colon: Mechanisms and implications for disease","volume":"82","author":"Kunzelmann","year":"2002","journal-title":"Physiol. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/thoraxjnl-2020-216368","article-title":"Rectal organoid morphology analysis (ROMA) as a promising diagnostic tool in cystic fibrosis","volume":"76","author":"Cuyx","year":"2021","journal-title":"Thorax"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Silva, I.A.L., Railean, V., Duarte, A., and Amaral, M.D. (2021). Personalized Medicine Based on Nasal Epithelial Cells: Comparative Studies with Rectal Biopsies and Intestinal Organoids. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050421"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ppul.23146","article-title":"Novel outcome measures for clinical trials in cystic fibrosis","volume":"50","author":"Tiddens","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jcf.2019.09.015","article-title":"Insights into the variability of nasal potential difference, a biomarker of CFTR activity","volume":"19","author":"Kyrilli","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2016.10.002","article-title":"Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor","volume":"16","author":"Fidler","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200508-1330OC","article-title":"Cystic Fibrosis Transmembrane Conductance Regulator Function Is Suppressed in Cigarette Smokers","volume":"173","author":"Cantin","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cca.2008.02.022","article-title":"Total intra-individual variation in sweat sodium and chloride concentrations for the diagnosis of cystic fibrosis","volume":"393","author":"Koerbin","year":"2008","journal-title":"Clin. Chim. Acta"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jcf.2016.11.008","article-title":"Biological variability of the sweat chloride in diagnostic sweat tests: A retrospective analysis","volume":"16","author":"Vermeulen","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12016-007-8039-9","article-title":"Chronic Inflammation in the Cystic Fibrosis Lung: Alterations in Inter- and Intracellular Signaling","volume":"34","author":"Nichols","year":"2008","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Carbone, A., Vitullo, P., Di Gioia, S., and Conese, M. (2023). Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies. Genes, 14.","DOI":"10.3390\/genes14101966"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Bernarde, C., Keravec, M., Mounier, J., Gouriou, S., Rault, G., F\u00e9rec, C., Barbier, G., and H\u00e9ry-Arnaud, G. (2015). Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124124"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ppul.23712","article-title":"CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy","volume":"52","author":"Guerra","year":"2017","journal-title":"Pediatr. Pulmonol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chest.2017.10.005","article-title":"CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores after CFTR Modulation with Ivacaftor","volume":"153","author":"Ronan","year":"2018","journal-title":"Chest"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"642180","DOI":"10.3389\/fimmu.2021.642180","article-title":"Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid","volume":"12","author":"Mainz","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S1569-1993(17)30437-X","article-title":"73 The effect of ivacaftor CFTR gene-potentiating therapy on cytokine levels in CF patients with the G551D mutation","volume":"16","author":"Wilson","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2017.08.013","article-title":"Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease","volume":"23","author":"White","year":"2017","journal-title":"eBioMedicine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/rccm.202012-4332LE","article-title":"Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis","volume":"204","author":"McNally","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Favia, M., Gallo, C., Guerra, L., De Venuto, D., Diana, A., Polizzi, A.M., Montemurro, P., Mariggi\u00f2, M.A., Leonetti, G., and Manca, A. (2020). Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi\u00ae) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072398"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e001590","DOI":"10.1136\/bmjresp-2022-001590","article-title":"ROCK STUDY in CF: Sustained anti-inflammatory effects of lumacaftor\u2013ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis\u2014An observational study","volume":"10","author":"Arooj","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1513\/AnnalsATS.202008-1054OC","article-title":"Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis","volume":"18","author":"Graeber","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e02251-22","DOI":"10.1128\/spectrum.02251-22","article-title":"Effects of Lumacaftor-Ivacaftor on Airway Microbiota-Mycobiota and Inflammation in Patients with Cystic Fibrosis Appear To Be Linked to Pseudomonas aeruginosa Chronic Colonization","volume":"11","author":"Enaud","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e54556","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Scambler","year":"2020","journal-title":"eLife"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/ppul.26334","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment reduces airway inflammation in cystic fibrosis","volume":"58","author":"Bennard","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in Cystic Fibrosis Patients with G551D-CFTR Treated with Ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jcf.2022.03.012","article-title":"Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D","volume":"21","author":"Hoppe","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"Munck","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jcf.2018.04.004","article-title":"Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations","volume":"18","author":"Guimbellot","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/ppul.24424","article-title":"Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations","volume":"54","author":"Salvatore","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision\u2014Making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1513\/pats.200703-044BR","article-title":"Sputum biomarkers of inflammation in cystic fibrosis lung disease","volume":"4","author":"Sagel","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1183\/09031936.00017713","article-title":"Clinimetric properties of bronchoalveolar lavage inflammatory markers in cystic fibrosis","volume":"43","author":"Fayon","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1164\/rccm.200609-1354OC","article-title":"Association between Pulmonary Function and Sputum Biomarkers in Cystic Fibrosis","volume":"175","author":"Aitken","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jcf.2021.10.009","article-title":"Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: Current understanding and gaps in knowledge","volume":"21","author":"Lepissier","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Abreu, S.C., Lopes-Pacheco, M., Weiss, D.J., and Rocco, P.R.M. (2021). Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.600711"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"dos Santos, C.C., Lopes-Pacheco, M., English, K., Rolandsson Enes, S., Krasnodembskaya, A., and Rocco, P.R.M. (2024). The MSC-EV-microRNAome: A Perspective on Therapeutic Mechanisms of Action in Sepsis and ARDS. Cells, 13.","DOI":"10.3390\/cells13020122"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"27066","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Siljander","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","article-title":"Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication","volume":"21","author":"Mathieu","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Di Gioia, S., Daniello, V., and Conese, M. (2022). Extracellular Vesicles\u2019 Role in the Pathophysiology and as Biomarkers in Cystic Fibrosis and COPD. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010228"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/bs.ctm.2018.09.002","article-title":"Endothelial Extracellular Vesicles in Pulmonary Function and Disease","volume":"Volume 82","author":"Letsiou","year":"2018","journal-title":"Current Topics in Membranes"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1165\/rcmb.2017-0293TR","article-title":"Extracellular Vesicles: New Players in Lung Immunity","volume":"58","author":"Fujita","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.molmed.2018.08.006","article-title":"Microenvironmental Influences on Extracellular Vesicle-Mediated Communication in the Lung","volume":"24","author":"Haggadone","year":"2018","journal-title":"Trends Mol. Med."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Su, G., Ma, X., and Wei, H. (2020). Multiple Biological Roles of Extracellular Vesicles in Lung Injury and Inflammation Microenvironment. BioMed Res. Int., 2020.","DOI":"10.1155\/2020\/5608382"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1465-9921-11-94","article-title":"Isolation and characterization of microparticles in sputum from cystic fibrosis patients","volume":"11","author":"Porro","year":"2010","journal-title":"Respir. Res."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Kadota, T., Fujita, Y., Yoshioka, Y., Araya, J., Kuwano, K., and Ochiya, T. (2016). Extracellular Vesicles in Chronic Obstructive Pulmonary Disease. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17111801"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/thoraxjnl-2020-216370","article-title":"Role of extracellular vesicles in chronic lung disease","volume":"76","author":"Trappe","year":"2021","journal-title":"Thorax"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2013.03.002","article-title":"Pro-inflammatory effect of cystic fibrosis sputum microparticles in the murine lung","volume":"12","author":"Porro","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jprot.2018.07.001","article-title":"Comparative proteomics of respiratory exosomes in cystic fibrosis, primary ciliary dyskinesia and asthma","volume":"185","author":"Bourderioux","year":"2018","journal-title":"J. Proteom."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/thoraxjnl-2019-214027","article-title":"Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis","volume":"75","author":"Useckaite","year":"2020","journal-title":"Thorax"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/JLB.3AB0321-149R","article-title":"Neutrophil-derived extracellular vesicles promote feed-forward inflammasome signaling in cystic fibrosis airways","volume":"112","author":"Forrest","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2023.02.005","article-title":"Investigating serum extracellular vesicles in Cystic Fibrosis","volume":"22","author":"Trappe","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nature09267","article-title":"Mammalian microRNAs predominantly act to decrease target mRNA levels","volume":"466","author":"Guo","year":"2010","journal-title":"Nature"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jcf.2017.11.005","article-title":"The expression of Mirc1\/Mir17\u201392 cluster in sputum samples correlates with pulmonary exacerbations in cystic fibrosis patients","volume":"17","author":"Krause","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1586\/eri.11.175","article-title":"Therapeutic modulation of miRNA for the treatment of proinflammatory lung diseases","volume":"10","author":"Hassan","year":"2012","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1183\/09031936.00163414","article-title":"miR-17 overexpression in cystic fibrosis airway epithelial cells decreases interleukin-8 production","volume":"46","author":"Oglesby","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1164\/rccm.201311-1986OC","article-title":"miR-31 Dysregulation in Cystic Fibrosis Airways Contributes to Increased Pulmonary Cathepsin S Production","volume":"190","author":"Weldon","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1165\/rcmb.2013-0160OC","article-title":"Expression of microRNA-93 and Interleukin-8 during Pseudomonas aeruginosa\u2014Mediated Induction of Proinflammatory Responses","volume":"50","author":"Fabbri","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.4049\/jimmunol.0902669","article-title":"miR-126 Is Downregulated in Cystic Fibrosis Airway Epithelial Cells and Regulates TOM1 Expression","volume":"184","author":"Oglesby","year":"2010","journal-title":"J. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jcf.2013.03.007","article-title":"Elevated levels of miR-145 correlate with SMAD3 down-regulation in Cystic Fibrosis patients","volume":"12","author":"Megiorni","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.4049\/jimmunol.1202960","article-title":"Regulation of Cystic Fibrosis Transmembrane Conductance Regulator by MicroRNA-145, -223, and -494 Is Altered in \u0394F508 Cystic Fibrosis Airway Epithelium","volume":"190","author":"Oglesby","year":"2013","journal-title":"J. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1042\/BJ20110672","article-title":"microRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene","volume":"438","author":"Gillen","year":"2011","journal-title":"Biochem. J."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1164\/rccm.201704-0732OC","article-title":"MicroRNA-145 Antagonism Reverses TGF-\u03b2 Inhibition of F508del CFTR Correction in Airway Epithelia","volume":"197","author":"Ambalavanan","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"11604","DOI":"10.1074\/jbc.M110.198390","article-title":"Elevated miR-155 Promotes Inflammation in Cystic Fibrosis by Driving Hyperexpression of Interleukin-8","volume":"286","author":"Bhattacharyya","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1038\/ncomms7221","article-title":"Pharmacological modulation of the AKT\/microRNA-199a-5p\/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation","volume":"6","author":"Zhang","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1165\/rcmb.2012-0430OC","article-title":"Post-Transcriptional Regulation of Cystic Fibrosis Transmembrane Conductance Regulator Expression and Function by MicroRNAs","volume":"49","author":"Ramachandran","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.ajpath.2014.12.022","article-title":"New Insights about miRNAs in Cystic Fibrosis","volume":"185","author":"Sonneville","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Bengtson, C., Silswal, N., Baumlin, N., Yoshida, M., Dennis, J., Yerrathota, S., Kim, M., and Salathe, M. (2022). The CFTR Amplifier Nesolicaftor Rescues TGF-\u03b21 Inhibition of Modulator-Corrected F508del CFTR Function. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810956"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/1\/93\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:46:07Z","timestamp":1760103967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/1\/93"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":155,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["jpm14010093"],"URL":"https:\/\/doi.org\/10.3390\/jpm14010093","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]}}}